141 related articles for article (PubMed ID: 16896103)
1. Effect of rimonabant on weight and cardiometabolic risk factors.
Gadde KM
JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103
[No Abstract] [Full Text] [Related]
2. Rimonabant, obesity and diabetes.
Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
[TBL] [Abstract][Full Text] [Related]
3. [Sleep disorders associated with treatment with rimonabant].
Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
[No Abstract] [Full Text] [Related]
4. [The endocannabinoid system and treatment of obesity].
Aronsen L
Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
[TBL] [Abstract][Full Text] [Related]
5. Depression and weight loss: opposite outcome for surgery and rimonabant?
Chaput JP; Tremblay A
Obes Rev; 2008 Sep; 9(5):504-7. PubMed ID: 18643944
[No Abstract] [Full Text] [Related]
6. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
Gadde KM; Allison DB
Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206
[No Abstract] [Full Text] [Related]
8. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the weight-loss drug rimonabant.
Blüher M
Lancet; 2008 Feb; 371(9612):555-6; author reply 556-7. PubMed ID: 18280321
[No Abstract] [Full Text] [Related]
10. [Rimonabant (Acomplia)].
Duh D; Vanddevijver A
J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
[No Abstract] [Full Text] [Related]
11. Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
Wright KL; Robertson DA; Moyer MP; Ward SG
Int J Cancer; 2008 Apr; 122(8):1920-1. PubMed ID: 18076045
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of the weight-loss drug rimonabant.
Després JP; Van Gaal L; Pi-Sunyer X; Scheen A
Lancet; 2008 Feb; 371(9612):555; author reply 556-7. PubMed ID: 18280320
[No Abstract] [Full Text] [Related]
13. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Di Marzo V
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
[No Abstract] [Full Text] [Related]
14. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
[No Abstract] [Full Text] [Related]
15. End of the line for cannabinoid receptor 1 as an anti-obesity target?
Jones D
Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
[TBL] [Abstract][Full Text] [Related]
16. Rimonabant and progression of atherosclerosis in obese persons.
Dora JM; Scheffel RS
JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
[No Abstract] [Full Text] [Related]
17. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.
Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422
[No Abstract] [Full Text] [Related]
18. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
[TBL] [Abstract][Full Text] [Related]
19. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
20. ADAGIO-Lipids gives promises but faces the setbacks.
Taskinen MR
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):339-40. PubMed ID: 19228609
[No Abstract] [Full Text] [Related]
[Next] [New Search]
